Amgen Company News

What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine? - Yahoo Finance

What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine? Yahoo Finance

Amgen loses in Harbour antibody patent case, ordered to pay $20M+ - Fierce Biotech

Amgen loses in Harbour antibody patent case, ordered to pay $20M+ Fierce Biotech

AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE - Amgen

AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Amgen

Amgen Ends Lobbying Relationship With DC Firm - Legis1

Amgen Ends Lobbying Relationship With DC Firm Legis1

Amgen's Diversified Business, Emerging Pipeline Drives Positive View, RBC Says - 富途牛牛

Amgen's Diversified Business, Emerging Pipeline Drives Positive View, RBC Says 富途牛牛

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape - PR Newswire

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape PR Newswire

Amgen owes $20.2 million in antibody patent lawsuit, US jury says - Reuters

Amgen owes $20.2 million in antibody patent lawsuit, US jury says Reuters

Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Amgen Inc. stock underperforms Wednesday when compared to competitors MarketWatch

FDA hearing on Amgen's Tavneos will include findings from an independent review - Fierce Pharma

FDA hearing on Amgen's Tavneos will include findings from an independent review Fierce Pharma

Jury sides with Harbour BioMed in Amgen patent dispute - ICLG

Jury sides with Harbour BioMed in Amgen patent dispute ICLG

A pharmaceutical company is trying to block Colorado’s first-in-the-nation drug price cap in court - The Colorado Sun

A pharmaceutical company is trying to block Colorado’s first-in-the-nation drug price cap in court The Colorado Sun

Internal documents reveal: Denmark sues Amgen for millions following MFN exit - medwatch.com

Internal documents reveal: Denmark sues Amgen for millions following MFN exit medwatch.com

Amgen Stock’s Gross Margin Story in Q1 2026: What the Numbers Say About a $468 Target - TIKR.com

Amgen Stock’s Gross Margin Story in Q1 2026: What the Numbers Say About a $468 Target TIKR.com

AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR - Amgen

AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR Amgen

Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch

Amgen Inc. stock outperforms competitors despite losses on the day MarketWatch

Is Amgen Inc. (AMGN) A Good Stock To Buy Now? - Yahoo Finance

Is Amgen Inc. (AMGN) A Good Stock To Buy Now? Yahoo Finance

An Important Update Regarding TAVNEOS® (avacopan) - Amgen

An Important Update Regarding TAVNEOS® (avacopan) Amgen

Amgen CEO Bob Bradway's 2025 Letter to Shareholders - Amgen

Amgen CEO Bob Bradway's 2025 Letter to Shareholders Amgen

Amgen Named One of Newsweek’s Most Trustworthy Companies in America 2026 - Amgen

Amgen Named One of Newsweek’s Most Trustworthy Companies in America 2026 Amgen

Amgen Named One of the 2026 World’s Most Ethical Companies® by Ethisphere - Amgen

Amgen Named One of the 2026 World’s Most Ethical Companies® by Ethisphere Amgen

Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now - Yahoo Finance

Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now Yahoo Finance

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE - Amgen

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE Amgen

Amgen Defends Rare Disease Drug in FDA Crosshairs - MedCity News

Amgen Defends Rare Disease Drug in FDA Crosshairs MedCity News

Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna - Yahoo Finance

Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna Yahoo Finance

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance

Amgen (AMGN) Stock Valuation Looks Split Between Analyst Targets And DCF Upside - simplywall.st

Amgen (AMGN) Stock Valuation Looks Split Between Analyst Targets And DCF Upside simplywall.st

Healthcare of Ontario Pension Plan Trust Fund Sells 64,867 Shares of Amgen Inc. $AMGN - MarketBeat

Healthcare of Ontario Pension Plan Trust Fund Sells 64,867 Shares of Amgen Inc. $AMGN MarketBeat

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance

Anjali Rao Joins Amgen India as Executive Director – Human Resources - hrtoday.in

Anjali Rao Joins Amgen India as Executive Director – Human Resources hrtoday.in

Amgen's Cambridge site head has no office, and neither does anyone else - The Business Journals

Amgen's Cambridge site head has no office, and neither does anyone else The Business Journals

Amgen taps research firm to reassess Tavneos data - Reuters

Amgen taps research firm to reassess Tavneos data Reuters

2025 at Amgen: Investing, Expanding, and Serving More Patients - Amgen

2025 at Amgen: Investing, Expanding, and Serving More Patients Amgen

Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now - Yahoo Finance

Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now Yahoo Finance

Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance

Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note Yahoo Finance

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE - Amgen

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE Amgen